ADMA Biologics Stock Forecast, Price & News

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

Is ADMA Biologics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics or view top-rated stocks.

How has ADMA Biologics' stock price been impacted by COVID-19 (Coronavirus)?

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADMA shares have decreased by 39.4% and is now trading at $1.40.
View which stocks have been most impacted by COVID-19.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for ADMA Biologics.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The biotechnology company earned $20.68 million during the quarter, compared to analysts' expectations of $18.58 million. ADMA Biologics had a negative trailing twelve-month return on equity of 71.69% and a negative net margin of 108.60%. During the same quarter in the previous year, the business posted ($0.19) earnings per share.
View ADMA Biologics' earnings history.

What price target have analysts set for ADMA?

5 analysts have issued 1 year price targets for ADMA Biologics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect ADMA Biologics' share price to reach $5.70 in the next year. This suggests a possible upside of 307.1% from the stock's current price.
View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts.

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:

• Adam S. Grossman, President, Chief Executive Officer & Director (LinkedIn Profile)
• Brian Lenz, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
• Kaitlin Kestenberg, Vice President-Compliance & Clinical Operations
• Lucy DeMario, Senior Director-Scientific & Data Analysis
• Michael Least, Vice President-Market Access & National Accounts

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ADMA Biologics' key competitors?

Some companies that are related to ADMA Biologics include Coherus BioSciences (CHRS), Molecular Partners (MOLN), Vaxcyte (PCVX), Immunocore (IMCR), Sangamo Therapeutics (SGMO), Immunovant (IMVT), SOPHiA Genetics (SOPH), Ocugen (OCGN), MeiraGTx (MGTX), Rubius Therapeutics (RUBY), Century Therapeutics (IPSC), Agenus (AGEN), Immatics (IMTX), Vaxart (VXRT) and Scholar Rock (SRRK).
View all of ADMA's competitors.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include First Hawaiian Bank (0.26%) and XR Securities LLC (0.00%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends for ADMA Biologics.

Which major investors are buying ADMA Biologics stock?

ADMA stock was purchased by a variety of institutional investors in the last quarter, including First Hawaiian Bank. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc, and Young Kwon.
View insider buying and selling activity for ADMA Biologics or or view top insider-buying stocks.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $1.40.

How much money does ADMA Biologics make?

ADMA Biologics has a market capitalization of $274.14 million and generates $42.22 million in revenue each year. The biotechnology company earns $-75.75 million in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does ADMA Biologics have?

ADMA Biologics employs 407 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is www.admabiologics.com.

Where are ADMA Biologics' headquarters?

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at (201) 478-5552, via email at [email protected], or via fax at 201-478-5553.